Health & Fitness
Health and Fitness
Health and Fitness
Wed, January 28, 2009
Tue, January 27, 2009 ZYNEX Announces AMEX Application Status
LITTLETON, Colo.--([ BUSINESS WIRE ])--Zynex, Inc. (OTCBB: [ ZYXI ]), a provider of pain management systems and electrotherapy products for medical patients with functional disability, announces that it has withdrawn its application to the NYSE Alternext US, formerly known as the American Stock Exchange (AMEX), due to the price per share no longer meeting a requirement of a minimum price of two dollars per share.
Thomas Sandgaard, President and CEO of Zynex commented: "We unfortunately no longer meet NYSE Alternext US' price per share requirement, but plan to re-apply for a listing on the NYSE Alternext US as soon as possible as we hopefully again meet the qualification requirements."
About Zynex
Zynex, Inc. (founded in 1996) engineers, manufactures, markets and sells its own design of electrotherapy medical devices in two distinct markets: standard digital electrotherapy products for pain relief and pain management; and the NeuroMove(TM) for stroke and spinal cord injury (SCI) rehabilitation. Zynex's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain.
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, acceptance of our products by hospitals and clinicians, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force and other risks described in our 10-KSB Report for the year ended December 31, 2007 and our 10-Q Report for the quarter ended September 30, 2008.
